Your browser doesn't support javascript.
loading
Comparison of rituximab efficacy in treatment-naive and refractory inflammatory myopathies: experiences from a tertiary care centre.
Manwatkar, Abhilasha; Naresh, Kancha; Mathew, John; Nair, Aditya V; Goel, Ruchika; Yadav, Bijesh; Prakash, John Antony Jude; Das, John Kumar; Sivadasan, Ajith.
Afiliação
  • Manwatkar A; Department of Clinical Immunology and Rheumatology, Christian Medical College Vellore, Vellore, India.
  • Naresh K; Department of Neuroscience, Christian Medical College Vellore, Vellore, India.
  • Mathew J; Department of Clinical Immunology and Rheumatology, Christian Medical College Vellore, Vellore, India.
  • Nair AV; Department of Neuroscience, Christian Medical College Vellore, Vellore, India.
  • Goel R; Department of Clinical Immunology and Rheumatology, Christian Medical College Vellore, Vellore, India.
  • Yadav B; Department of Biostatistics, Christian Medical College Vellore, Vellore, India.
  • Prakash JAJ; Department of Clinical Microbiology, Christian Medical College Vellore, Vellore, India.
  • Das JK; Department of Clinical Immunology and Rheumatology, Christian Medical College Vellore, Vellore, India.
  • Sivadasan A; Department of Neuroscience, Christian Medical College Vellore, Vellore, India.
Article em En | MEDLINE | ID: mdl-38814804
ABSTRACT

OBJECTIVES:

To find out if Rituximab (RTX) is effective in "treatment naive" idiopathic inflammatory myopathies (IIM), and whether there could be differential treatment responses between the "treatment naive" and treatment "refractory" IIM.

METHODS:

Data obtained from a prospectively maintained database comprising patients with IIM treated with rituximab. Patient details were obtained at baseline, 3-months, 6-months intervals, and subsequent follow up visits. Treatment response was categorised as improved, worsening, or stable based on manual muscle testing (MMT8) scores, patient global and physician global improvement (PtGA and PGA) for skin and joint symptoms improvement and spirometry at 6 months. The time to clinical improvement and remission were noted and survival analysis curves were constructed.

RESULTS:

60 patients with IIM (including 18 with anti-SRP myopathy) were included, out of which 33 who received RTX were treatment naïve. The remaining 27 were started on rituximab for refractory myopathy. Mean age was 39 years (SD12.58) in "treatment-naive" group and 43 years (SD 12.12) in "refractory" group. At 6 months of follow up, 48/55 (87%) patients showed response, 31/31 (100%) in "treatment-naive" and 17/24 (70%) in "refractory" cases, p 0.006*. In refractory group, 7 (29%) had stable disease. The mean changes in MMT8 were significantly more in the "treatment-naive" treatment group (13.41(SD 7.31) compared with "refractory" IIM 8.33 (SD 7.92) (p= 0.017*). Majority of patients were able to reduce dose below 5 mg/day before 6 months. No major adverse events were reported over the median follow-up of 24 (IQR 36) months.

CONCLUSIONS:

Rituximab is effective and safe across the spectrum of IIM. Early use in disease is associated with better outcomes.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article